Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tarceva Pancreatic Cancer Indication Turned Down In The EU

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.

You may also be interested in...



EMEA’s CHMP Reverses Stance On Roche’s Tarceva

CHMP also recommends marketing authorization for J&J’s Prezista and Orphan Europe SARL’s Cystadane.

EMEA’s CHMP Reverses Stance On Roche’s Tarceva

CHMP also recommends marketing authorization for J&J’s Prezista and Orphan Europe SARL’s Cystadane.

Roche Appeals Negative EMEA Decision For Tarceva Pancreatic Cancer Indication

EMEA has 60 days to review Tarceva on appeal; the oncologic is approved for treatment of advanced pancreatic cancer in the U.S.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS064602

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel